Disease · MONDO_0011849

psoriatic arthritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. psoriatic arthritis. Diseases, record MONDO_0011849. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011849

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: psoriatic arthritis; Open Targets
Open Targets ID: MONDO_0011849; Open Targets
Other names: Arthritic Psoriasis, Arthritis, Psoriatic, PsA, Psoriasis Arthropathica, Psoriasis, Arthritic, arthritis psoriatica, arthropathic psoriasis; Open Targets
Disease Ontology: DOID:9008; Disease Ontology
MeSH: D015535; MeSH
NCI Thesaurus: C61277; NCI Thesaurus
Orphanet: ORPHA:40050; Orphanet
Highest stage of its drugs: Approval, for 25 of its 77 drugs, from DailyMed, EMA Human Drugs and PMDA; Open Targets

Drugs77

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ADALIMUMAB	CHEMBL1201580	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	53	30	30	Drugs and targets
SECUKINUMAB	CHEMBL1743068	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	29	25	25	Drugs and targets
ETANERCEPT	CHEMBL1201572	Protein	Approval	DailyMed and EMA Human Drugs	33	24	24	Drugs and targets
APREMILAST	CHEMBL514800	Small molecule	Approval	DailyMed, EMA Human Drugs and PMDA	24	19	19	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Approval	EMA Human Drugs	21	19	19	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Approval	DailyMed and EMA Human Drugs	24	16	16	Drugs and targets
GOLIMUMAB	CHEMBL1201833	Antibody	Approval	DailyMed and EMA Human Drugs	20	15	15	Drugs and targets
GUSELKUMAB	CHEMBL2364648	Antibody	Approval	DailyMed and PMDA	17	14	14	Drugs and targets
USTEKINUMAB	CHEMBL1201835	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	29	11	11	Drugs and targets
IXEKIZUMAB	CHEMBL1743034	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	13	9	9	Drugs and targets

1 to 10 of 77

See all 77 drugs

Targets102

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	10	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
IL17A	Interleukin-17A	8	Interleukin 17A inhibitor	Approval	https://conductscience.org/library/genes/3605	Drugs and targets
TNF	Tumor necrosis factor	6	TNF-alpha inhibitor	Approval	https://conductscience.org/library/genes/7124	Drugs and targets
TYK2	Janus Kinase (JAK)	6	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Approval	https://conductscience.org/library/genes/7297	Drugs and targets
JAK1	Janus Kinase (JAK)	5	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
IL12B	Interleukin-12	4	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Approval	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	4	Interleukin-23 inhibitor	Approval	https://conductscience.org/library/genes/51561	Drugs and targets
JAK2	Janus Kinase (JAK)	4	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	4	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Approval	https://conductscience.org/library/genes/3718	Drugs and targets
CNR1	Cannabinoid receptor 1	2	Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/1268	Drugs and targets

1 to 10 of 102

See all 102 targets

Trials232

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01623752	Prospective Evaluation of the Radiographic Efficacy of Enbrel		1,821	2019-08-16	Rheumatoid Arthritis, Psoriasis Arthritis	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT03104400	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)	Phase 3	1,705	2022-01-25	Psoriatic Arthritis	UPADACITINIB	Its record names the disease	ClinicalTrials.gov
NCT01313858	A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)		1,613	2016-11-01	Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing	GOLIMUMAB, METHOTREXATE	Its record names the disease	ClinicalTrials.gov
NCT02486302	A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.		1,534	2019-06-24	Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Plaque Psoriasis	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT00293722	Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists		1,308	2014-02-26	Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous	ETANERCEPT	Its record names the disease	ClinicalTrials.gov
NCT00760669	An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants		1,061	2013-08-12	Spondylitis, Ankylosing, Arthritis, Rheumatoid, Psoriasis, Arthritis, Psoriatic	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT04882098	A Study of Guselkumab in Participants With Active Psoriatic Arthritis	Phase 3	1,054	2026-02-04	Arthritis, Psoriatic	GUSELKUMAB	Its record names the disease	ClinicalTrials.gov
NCT02404350	Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis	Phase 3	997	2019-06-28	Psoriatic Arthritis	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT03675308	A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	Phase 3	964	2022-02-24	Psoriatic Arthritis	RISANKIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02745080	Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis	Phase 3	853	2021-01-27	Psoriatic Arthritis	ADALIMUMAB, SECUKINUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 232

See all 232 trials

Comparisons in its trials105

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Risankizumab vs Placebo: deaths from any cause	1 of 483	0 of 481	964	NCT03675308	Trial comparisons
Risankizumab vs Placebo: serious adverse events	12 of 483	18 of 481	964	NCT03675308	Trial comparisons
Etanercept BIW/QW vs Etanercept QW/QW: Number of Patients Achieving Clear or Almost Clear on Physician Global Assessment (PGA) of Psoriasis	176 of 379	119 of 373	752	NCT00245960	Trial comparisons
Adalimumab + Placebo vs Adalimumab + Calcipotriol/Betamethasone: serious adverse events	15 of 364	16 of 366	730	NCT00574249	Trial comparisons
Deucravacitinib vs Placebo: Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16	169 of 312	123 of 312	624	NCT04908189	Trial comparisons
Deucravacitinib vs Placebo: Number of Participants Meeting American College of Rheumatology (ACR) 50 at Week 16	90 of 312	51 of 312	624	NCT04908189	Trial comparisons
Deucravacitinib vs Placebo: Number of Participants Meeting American College of Rheumatology (ACR) 70 at Week 16	33 of 312	17 of 312	624	NCT04908189	Trial comparisons
Deucravacitinib vs Placebo: Number of Participants Meeting Achievement of Minimal Disease Activity (MDA) at Week 16	80 of 312	46 of 312	624	NCT04908189	Trial comparisons
Ixekizumab vs Adalimumab: Number of Participants Who Answered Yes to Any 10 Questions in Columbia Suicide Severity Rating Scale (C-SSRS)	9 of 283	7 of 283	566	NCT03151551	Trial comparisons
AIN457 6 mg/kg - 3 mg/kg i.v vs Placebo up to Week 16: deaths from any cause	0 of 374	1 of 190	564	NCT04209205	Trial comparisons

1 to 10 of 105

See all 105 comparisons in its trials

Papers from its trials385

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42386286	RESULT	3	PubMed
42152504	RESULT	3	PubMed
41838419	RESULT	3	PubMed
41381988	RESULT	3	PubMed
41053449	RESULT	1	PubMed
40347389	RESULT	3	PubMed
39534481	RESULT	3	PubMed
39120849	RESULT	5	PubMed
38754125	RESULT	3	PubMed
38488975	RESULT	5	PubMed

1 to 10 of 385

See all 385 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011849

GET https://conductscience.org/api/diseases/v1/MONDO_0011849/drugs?page=2

API reference For AI assistants